Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 400 microgram - nasal drops - excipient ingredients: polysorbate 20; sorbitan monolaurate; monobasic sodium phosphate; dibasic sodium phosphate; sodium chloride; water for injections - indications: for the treatment of mild to moderate nasal polyps and associated symptoms of nasal obstruction in adults and adolescents over 16 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - aciclovir -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - aciclovir -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 2.4 mg/ml (equivalent: salbutamol, qty 2 mg/ml) - inhalation - excipient ingredients: sodium chloride; sulfuric acid; water for injections - indications as at 1st february 1999: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 1.2 mg/ml (equivalent: salbutamol, qty 1 mg/ml) - inhalation - excipient ingredients: sodium chloride; water for injections; sulfuric acid - indications as at 1st february 1999: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - aciclovir -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - tretinoin -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - mupirocin calcium, quantity: 21.5 mg/g (equivalent: mupirocin, qty 20 mg/g) - ointment - excipient ingredients: white soft paraffin; bis-diglyceryl polyacyladipate-2 - bactroban (mupirocin) nasal ointment is indicated for the elimination of nasal carriage of staphylococci including methicillin resistant staphylococcus aureus (mrsa).

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - mupirocin, quantity: 22 mg/g - ointment - excipient ingredients: macrogol 3350; macrogol 400 - bacrtoban (mupirocin) ointment is indicated for the topical treatment of mild impetigo.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis a virus antigen, quantity: 720 elisa unit - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; aluminium; polysorbate 20; dibasic sodium phosphate heptahydrate; monobasic potassium phosphate; sodium chloride; potassium chloride; water for injections; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - havrix is indicated for active immunisation against hepatitis a virus (hav) infection in susceptible subjects at risk of exposure to hav. havrix junior is indicated in subjects aged 2 to 15 years and havrix 1440 is indicated in subjects aged 16 years and older. in areas of low prevalence of hepatitis a, immunisation with havrix is particularly recommended in the following subjects: travellers : persons travelling to areas of intermediate or high endemicity for hepatitis a. these areas include africa, asia, india, the pacific islands, the mediterranean basin, the middle east, central and south america. armed forces : armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of hav infection. persons for whom hepatitis a is an occupational hazard or for whom there is an increased risk of transmission. these include: employees in day-care centres particularly in situations where children have not been toilet trained; teachers and other close contacts of the intellectually disabled; staff and residents of residential facilities for the intellectually disabled; health workers and teachers in remote aboriginal and torres strait islander communities; nursing staff and other healthcare workers in contact with patients in paediatric wards, infectious diseases wards, emergency rooms and intensive care units sewerage workers ; food handlers, since food hygiene procedures and food processing methods are not always adequate to protect from contamination from food handlers. homosexual men : increased incidence of hepatitis a infection among homosexual males suggests that the disease may be sexually transmitted in this group. contacts of infected persons : since virus shedding from infected persons may occur for a prolonged period, active immunisation of close contacts is recommended. the use of vaccine in outbreak control has been shown to be more effective than the use of immunoglobulin. specific population groups known to have a higher incidence of hepatitis a: eg. australian aboriginals, recognised community-wide hav epidemics. individuals with chronic liver disease and recipients of liver transplants, as hepatitis a infections is likely to be more severe in these groups. many injecting drug users will have pre-existing liver disease from hepatitis b or hepatitis c infection. recipients of blood products, such as factor viii eg. haemophiliacs. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis d virus, hepatitis e or other pathogens known to infect the liver.